Search the Appendices of Resolution CM/Res(2018)1
1920 found
INN | ATC Code ▼ | Country | Classification | Last update | MA Number | Registration date | Status | |
---|---|---|---|---|---|---|---|---|
BORTEZOMIB | L01XG01 | FR | I | VALID | ||||
TRETINOIN | L01XF01 | FR | I | 23-01-2019 | FR/H/0106/001/II/030 | 22-10-2008 | VALID | |
FEDRATINIB | L01XE57 | FR | I | 12-10-2021 | EMEA/H/C/005026 | 08-02-2021 | VALID | |
PADELIPORFIN | L01XD07 | FR | I | 10-04-2018 | EMEA/H/C/004182 | 15-11-2017 | VALID | |
AMINOLEVULINIC ACID | L01XD04 | FR | I | 23-02-2017 | VALID | |||
CETUXIMAB | L01XC06 | FR | I | VALID | ||||
TRASTUZUMAB | L01XC03 | FR | I | 14-05-2024 | EMEA/H/C/005769 | 15-11-2023 | VALID | |
OXALIPLATIN | L01XA03 | FR | I | FR/H/0284/002/ | 12-03-2015 | VALID | ||
NIVOLUMAB AND RELATLIMAB | L01FY02 | FR | I | 27-02-2023 | EMEA/H/C/005481 | 15-09-2022 | VALID | |
PERTUZUMAB AND TRASTUZUMAB | L01FY01 | FR | I | VALID | ||||
ELRANATAMAB | L01FX32 | FR | I | 14-05-2024 | EMEA/H/C/005908 | 07-12-2023 | VALID | |
ZOLBETUXIMAB | L01FX31 | FR | I | 29-10-2024 | EMEA/H/C/005868 | 19-09-2024 | VALID | |
TALQUETAMAB | L01FX29 | FR | I | 14-11-2023 | EMEA/H/C/005864 | 21-08-2023 | VALID | |
GLOFITAMAB | L01FX28 | FR | I | 14-11-2023 | EMEA/H/C/005751 | 07-07-2023 | VALID | |
MIRVETUXIMAB SORAVTANSINE | L01FX26 | FR | I | 02-05-2025 | EMEA/H/C/005036 | 14-11-2024 | VALID | |
LONCASTUXIMAB TESIRINE | L01FX22 | FR | I | 30-05-2023 | EMEA/H/C/005685 | 20-12-2022 | VALID | |
TREMELIMUMAB | L01FX20 | FR | I | 30-05-2023 | EMEA/H/C/004650 | 20-02-2023 | VALID | |
AMIVANTAMAB | L01FX18 | FR | I | 25-04-2022 | EMEA/H/C/005454 | 09-12-2021 | VALID | |
SACITUZUMAB GOVITECAN | L01FX17 | FR | I | 25-04-2022 | EMEA/H/C/005182 | 22-11-2021 | VALID | |
POLATUZUMAB VEDOTIN | L01FX14 | FR | I | 22-04-2020 | EMEA/H/C/004870 | 16-01-2020 | VALID | |
ENFORTUMAB VEDOTIN | L01FX13 | FR | I | 27-02-2023 | EMEA/H/C/005392 | 13-04-2022 | VALID | |
TAFASITAMAB | L01FX12 | FR | I | 12-10-2021 | EMEA/H/C/005436 | 26-08-2021 | VALID | |
OLARATUMAB | L01FX10 | FR | Not authorised | 27-01-2022 | VALID | |||
MOGAMULIZUMAB | L01FX09 | FR | I | 21-10-2019 | EMEA/H/C/004232 | 22-11-2018 | VALID | |
ELOTUZUMAB | L01FX08 | FR | I | 07-11-2016 | EMEA/H/C/003967 | 11-05-2016 | VALID | |
BLINATUMOMAB | L01FX07 | FR | I | EMEA/H/C/003731 | 23-11-2015 | VALID | ||
DINUTUXIMAB BETA | L01FX06 | FR | I | EMEA/H/C/003918 | 08-05-2017 | VALID | ||
BRENTUXIMAB VEDOTIN | L01FX05 | FR | I | VALID | ||||
IPILIMUMAB | L01FX04 | FR | I | VALID | ||||
CATUMAXOMAB | L01FX03 | FR | I | 02-05-2025 | EMEA/H/C/005697 | 10-02-2025 | VALID | |
GEMTUZUMAB OZOGAMICIN | L01FX02 | FR | I | 12-11-2018 | EMEA/H/C/004204 | 21-09-2018 | VALID | |
RAMUCIRUMAB | L01FG02 | FR | I | VALID | ||||
TORIPALIMAB | L01FF13 | FR | I | 29-10-2024 | EMEA/H/C/006120 | 19-09-2024 | VALID | |
SERPLULIMAB | L01FF12 | FR | I | 02-05-2025 | EMEA/H/C/006170 | 03-02-2025 | VALID | |
RETIFANLIMAB | L01FF10 | FR | I | 29-10-2024 | EMEA/H/C/006194 | 19-04-2024 | VALID | |
TISLELIZUMAB | L01FF09 | FR | I | 14-11-2023 | EMEA/H/C/005919 | 15-09-2023 | VALID | |
DOSTARLIMAB | L01FF07 | FR | I | 12-10-2021 | EMEA/H/C/005204 | 21-04-2021 | VALID | |
CEMIPLIMAB | L01FF06 | FR | I | EMEA/H/C/004844 | 27-06-2019 | VALID | ||
ATEZOLIZUMAB | L01FF05 | FR | I | EMEA/H/C/004143 | 21-09-2017 | VALID | ||
AVELUMAB | L01FF04 | FR | I | EMEA/H/C/004338 | 18-09-2017 | VALID | ||
DURVALUMAB | L01FF03 | FR | I | 12-11-2018 | EMEA/H/C/004771 | 20-09-2018 | VALID | |
PEMBROLIZUMAB | L01FF02 | FR | I | 07-04-2016 | EMEA/H/C/003820 | 17-07-2015 | VALID | |
NIVOLUMAB | L01FF01 | FR | I | 07-04-2016 | EMEA/H/C/003985 | 19-06-2015 | VALID | |
NECITUMUMAB | L01FE03 | FR | Not authorised | 27-01-2022 | VALID | |||
PANITUMUMAB | L01FE02 | FR | I | VALID | ||||
TRASTUZUMAB DERUXTECAN | L01FD04 | FR | I | 12-10-2021 | EMEA/H/C/005124 | 18-01-2021 | VALID | |
TRASTUZUMAB EMTANSINE | L01FD03 | FR | I | 27-01-2022 | VALID | |||
PERTUZUMAB | L01FD02 | FR | I | VALID | ||||
TRASTUZUMAB | L01FD01 | FR | I | VALID | ||||
ISATUXIMAB | L01FC02 | FR | I | 03-03-2021 | EMEA/H/C/004977 | 30-05-2020 | VALID |